

Arkusz Skalniak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5605771/publications.pdf>

Version: 2024-02-01

43
papers

1,715
citations

331259

21
h-index

288905

40
g-index

47
all docs

47
docs citations

47
times ranked

2158
citing authors

#	ARTICLE	IF	CITATIONS
1	Biphenyl Ether Analogs Containing Pomalidomide as Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction. <i>Molecules</i> , 2022, 27, 3454.	1.7	5
2	Macrocyclic Peptide Inhibitor of PD-1/PD-L1 Immune Checkpoint. <i>Advanced Therapeutics</i> , 2021, 4, 2000195.	1.6	5
3	Human and mouse PD-L1: similar molecular structure, but different druggability profiles. <i>IScience</i> , 2021, 24, 101960.	1.9	45
4	Application of bioorthogonal hetero-Diels-Alder cycloaddition of 5-arylidene derivatives of 1,3-dimethylbarbituric acid and vinyl thioether for imaging inside living cells. <i>Organic and Biomolecular Chemistry</i> , 2021, 19, 6045-6058.	1.5	0
5	Germacranolides from <i>Carpesium divaricatum</i> : Some New Data on Cytotoxic and Anti-Inflammatory Activity. <i>Molecules</i> , 2021, 26, 4644.	1.7	4
6	Terphenyl-Based Small-Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein-Protein Interaction. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 11614-11636.	2.9	42
7	PD-L1 Inhibitors: Different Classes, Activities, and Mechanisms of Action. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11797.	1.8	18
8	Early Recognition of the PCL/Fibrous Carbon Nanocomposites Interaction with Osteoblast-like Cells by Raman Spectroscopy. <i>Nanomaterials</i> , 2021, 11, 2890.	1.9	9
9	Systematic α -foldamerization™ of peptide inhibiting p53-MDM2/X interactions by the incorporation of trans- or cis-2-aminocyclopentanecarboxylic acid residues. <i>European Journal of Medicinal Chemistry</i> , 2020, 208, 112814.	2.6	11
10	Does 2D correlation Raman spectroscopy distinguish polymer nanomaterials due to the nanoaddition?. <i>Journal of Molecular Structure</i> , 2020, 1217, 128342.	1.8	5
11	Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 11271-11285.	2.9	45
12	Anti-CD44 DNA Aptamers Selectively Target Cancer Cells. <i>Nucleic Acid Therapeutics</i> , 2020, 30, 289-298.	2.0	13
13	A 2D-Raman correlation spectroscopy study of the interaction of the polymer nanocomposites with carbon nanotubes and human osteoblast-like cells interface. <i>Journal of Molecular Structure</i> , 2020, 1212, 128135.	1.8	8
14	Multicomponent Peptide Stapling as a Diversity-Driven Tool for the Development of Inhibitors of Protein-Protein Interactions. <i>Angewandte Chemie</i> , 2020, 132, 5273-5279.	1.6	6
15	Multicomponent Peptide Stapling as a Diversity-Driven Tool for the Development of Inhibitors of Protein-Protein Interactions. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 5235-5241.	7.2	29
16	Resveratrol enhances apoptosis induced by the heterocyclic aromatic amines in p53-wt LoVo cells, but not in p53-deficient HaCaT cells. <i>Acta Biochimica Polonica</i> , 2020, 67, 605-611.	0.3	1
17	Hitting on the move: Targeting intrinsically disordered protein states of the MDM2-p53 interaction. <i>European Journal of Medicinal Chemistry</i> , 2019, 182, 111588.	2.6	9
18	CA-170 α A Potent Small-Molecule PD-L1 Inhibitor or Not?. <i>Molecules</i> , 2019, 24, 2804.	1.7	103

#	ARTICLE	IF	CITATIONS
19	Design, Synthesis, Evaluation, and Structural Studies of <i>C₂</i> -Symmetric Small Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein-Protein Interaction. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 7250-7263.	2.9	71
20	Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists. <i>Cancers</i> , 2019, 11, 1014.	1.7	25
21	A fluorinated indole-based <i>MDM2</i> antagonist selectively inhibits the growth of p53 ^{wt} osteosarcoma cells. <i>FEBS Journal</i> , 2019, 286, 1360-1374.	2.2	13
22	A therapeutic patent overview of MDM2/X-targeted therapies (2014-2018). <i>Expert Opinion on Therapeutic Patents</i> , 2019, 29, 151-170.	2.4	30
23	Raman microspectroscopic investigations of polymer nanocomposites: evaluation of physical and biophysical properties. <i>International Journal of Polymeric Materials and Polymeric Biomaterials</i> , 2019, 68, 44-52.	1.8	13
24	Identification of small-molecule inhibitors of USP2a. <i>European Journal of Medicinal Chemistry</i> , 2018, 150, 261-267.	2.6	24
25	p38 but not p53 is responsible for UVA-induced MCP1 expression. <i>Mechanisms of Ageing and Development</i> , 2018, 172, 96-106.	2.2	8
26	Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells. <i>Cancers</i> , 2018, 10, 396.	1.7	49
27	1,4,5-Trisubstituted Imidazole-Based p53-MDM2/MDMX Antagonists with Aliphatic Linkers for Conjugation with Biological Carriers. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 4234-4244.	2.9	29
28	Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 5857-5867.	2.9	242
29	Lithocholic Acid Hydroxyamide Destabilizes Cyclin D1 and Induces G ₀ /G ₁ Arrest by Inhibiting Deubiquitinase USP2a. <i>Cell Chemical Biology</i> , 2017, 24, 458-470.e18.	2.5	41
30	MCP1 contributes to the inflammatory response of UVB-treated keratinocytes. <i>Journal of Dermatological Science</i> , 2017, 87, 10-18.	1.0	12
31	Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint. <i>Angewandte Chemie</i> , 2017, 129, 13920-13923.	1.6	13
32	Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint. <i>Angewandte Chemie - International Edition</i> , 2017, 56, 13732-13735.	7.2	131
33	Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells. <i>Oncotarget</i> , 2017, 8, 72167-72181.	0.8	221
34	MCP1 contributes to the toxicity of proteasome inhibitor MG-132 in HeLa cells by the inhibition of NF- κ B. <i>Molecular and Cellular Biochemistry</i> , 2014, 395, 253-263.	1.4	13
35	Proteasome inhibitor <i>MG-132</i> induces <i>MCP1</i> expression. <i>FEBS Journal</i> , 2013, 280, 2665-2674.	2.2	26
36	Effect of silver nanoparticles on human primary keratinocytes. <i>Biological Chemistry</i> , 2013, 394, 113-123.	1.2	46

#	ARTICLE	IF	CITATIONS
37	Effects triggered by platinum nanoparticles on primary keratinocytes. <i>International Journal of Nanomedicine</i> , 2013, 8, 3963.	3.3	45
38	Metastases inhibition and cellular damage in melanoma cells irradiated with proton beam. <i>Acta Ophthalmologica</i> , 2013, 91, 0-0.	0.6	0
39	Limited GADD45 β expression and function in IL-1 β toxicity towards insulin-producing cells. <i>Acta Biochimica Polonica</i> , 2013, 60, 595-602.	0.3	1
40	Effects of the novel mitochondrial protein mimitin in insulin-secreting cells. <i>Biochemical Journal</i> , 2012, 445, 349-359.	1.7	11
41	Monocyte chemotactic protein-1-induced protein-1 (MCPIP1) is a novel multifunctional modulator of inflammatory reactions. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2012, 1823, 1905-1913.	1.9	78
42	Regulatory feedback loop between NF κ B and MCP1-induced protein 1 RNase. <i>FEBS Journal</i> , 2009, 276, 5892-5905.	2.2	91
43	Conserved Conformational Changes in the ATPase Cycle of Human Hsp90. <i>Journal of Biological Chemistry</i> , 2008, 283, 17757-17765.	1.6	120